SHERRYL LUVIS: Open Payments
NPI 1275812851 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,076 in 74 payments from 13 companies in 2025. Trend: 2023 $949 · 2024 $906 · 2025 $1,076
Food & beverage: $1,076
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $289 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $213 |
| Novo Nordisk Inc | 10 | $139 |
| Otsuka America Pharmaceutical, Inc. | 6 | $137 |
| AstraZeneca Pharmaceuticals LP | 4 | $75 |
| Lilly USA, LLC | 4 | $75 |
| Phathom Pharmaceuticals, Inc. | 5 | $48 |
| ALK-Abello, Inc | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
Products named: VRAYLAR, CAPLYTA, REXULTI, Wegovy, AIRSUPRA, MOUNJARO, VOQUEZNA, Ozempic.
Industry payments across CO — which companies pay providers there.
